New onset of Susac syndrome after mRNA COVID-19 vaccine: a case report
J Neurol
.
2023 Feb;270(2):614-617.
doi: 10.1007/s00415-022-11406-2.
Epub 2022 Oct 12.
Authors
Assunta Bianco
1
2
,
Francesca Colò
3
,
Silvia Falso
3
,
Rosellina Russo
4
5
,
Matteo Maria Carlà
6
,
Angelo Minucci
7
,
Gabriella Cadoni
8
9
,
Matteo Lucchini
10
3
,
Alessandra Cicia
3
,
Paolo Calabresi
10
3
,
Massimiliano Mirabella
10
3
Affiliations
1
Multiple Sclerosis Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy. assunta.bianco@unicatt.it.
2
Department of Neurosciences, Catholic University of Sacred Heart, 00168, Rome, Italy. assunta.bianco@unicatt.it.
3
Department of Neurosciences, Catholic University of Sacred Heart, 00168, Rome, Italy.
4
Neuroradiology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
5
Institute of Radiology, Catholic University of Sacred Heart, 00168, Rome, Italy.
6
Institute of Ophtalmology, Catholic University of Sacred Heart, 00168, Rome, Italy.
7
Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
8
Otorhinolaryngology Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
9
Department of Otorhinolaryngology, Catholic University of Sacred Heart, 00168, Rome, Italy.
10
Multiple Sclerosis Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168, Rome, Italy.
PMID:
36222903
PMCID:
PMC9555271
DOI:
10.1007/s00415-022-11406-2
No abstract available
Publication types
Case Reports
Letter
MeSH terms
COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Magnetic Resonance Imaging
RNA, Messenger
Susac Syndrome* / etiology
Substances
COVID-19 Vaccines
RNA, Messenger